Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Novavax Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.85 (market cap $7.07B), while Novavax Inc trades at $9.9 (market cap $1.68B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | NVAX | |
|---|---|---|
Market Cap | $7.07B | $1.68B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $11.19 |
52-Week Low | $14.79 | $6.22 |
Enterprise Value | $21.88B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals but attractive valuation metrics including a P/E of 9.33 and P/S of 0.74. The company has beaten earnings estimates for three consecutive quarters, though Q3 2026 faces a higher bar at $0.89 EPS. Recent news highlights fuel cost pressures from rising oil prices, contributing to the stock's recent decline despite positive operational developments like new waterpark openings and fleet expansion.
NCLH presents a value opportunity with strong profitability metrics (36.73% ROE) and analyst consensus price target of $20.25 (32% upside), but faces significant risks from fuel cost volatility, high leverage (debt-to-asset ratio 64.79%), and competitive pressure. The company's turnaround plan focusing on cost controls and fleet optimization must overcome macroeconomic headwinds to drive sustained recovery.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
